[Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].

@article{Wenger1998HormoneTO,
  title={[Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].},
  author={Frank Axel Wenger and Hans U. Zieren and Ch. A. Jacobi and Jochen M. M{\"u}ller},
  journal={Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress},
  year={1998},
  volume={115},
  pages={1348-50}
}
In a prospective trial a combination of octreotide and tamoxifen was evaluated for its effect on tumour recurrence of R0-resected pancreatic carcinoma. Compared to the control group (n = 14), which was treated according to "best supportive care", the median survival times for the octreotide-tamoxifen group (n = 14) were 7 and 3.5 months respectively. In the octreotide-tamoxifen group patients suffered less from nausea, pain and fatigue (p < 0.05). Furthermore, there was a benefit of octreotide… CONTINUE READING